# OPTIMIZE (NCT06001385)

> HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06001385
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Center for International Blood and Marrow Transplant Research
- Conditions: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Leukemia; Myelodysplastic Syndromes; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Neoplasm; Lymphoma; Chronic Myelomonocytic Leukemia; Pro-Lymphocytic Leukemia; Myelofibrosis
- Interventions: Busulfan; Fludarabine; PBSC Hematopoietic Stem Cell Transplantation (HSCT); Post-Transplant Cyclophosphamide; Mesna; Tacrolimus; Mycophenolate Mofetil; Patient Reported Outcomes; Melphalan; Total-body irradiation; Cyclophosphamide
- Enrollment: 313
- Primary outcome: Infection Free Survival

## HCP commentary on OPTIMIZE so far

What clinicians have said in podcasts, YouTube videos and X posts we have indexed. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=optimize-nct06001385